UNITED KINGDOM —Qureight has completed a USD 20 million Series B financing round, providing fresh capital to scale its artificial intelligence-powered imaging platform used in pharmaceutical clinical trials, according to an official company announcement. The funding will be directed toward expanding the company's technology capabilities, growing its international operations and strengthening collaborations with pharmaceutical and biotechnology companies developing therapies for lung and cardiovascular diseases.
The investment reflects increasing demand for advanced imaging analytics that can generate objective clinical endpoints and improve the efficiency of drug development. As pharmaceutical companies seek to shorten trial timelines, reduce development risk and improve patient selection, AI-enabled image analysis is becoming an increasingly important component of modern clinical research. Qureight's platform combines quantitative imaging biomarkers with clinical data management to provide more detailed assessments of disease progression and treatment response.
The financing also highlights continued investor interest in technology platforms operating at the intersection of healthcare, artificial intelligence and clinical research. Wider adoption of AI-based imaging solutions could influence contract research organizations, biotechnology companies, healthcare providers and pharmaceutical manufacturers by enabling more standardized and data-driven clinical trial processes. The development is particularly relevant for respiratory and cardiovascular drug pipelines, where imaging plays a central role in evaluating therapeutic outcomes.
For investors and industry participants, the funding demonstrates sustained capital flows into health technology companies developing specialized AI applications with commercial relevance in regulated healthcare markets. Successful deployment of advanced imaging biomarkers could improve clinical trial productivity while supporting regulatory-quality evidence generation, creating opportunities for broader adoption across global drug development programs.
Founded in Cambridge, United Kingdom, Qureight develops AI-powered imaging and clinical data platforms designed for pharmaceutical research. The company focuses on quantitative imaging biomarkers that support clinical trials in respiratory and cardiovascular diseases and collaborates with pharmaceutical, biotechnology and healthcare organizations worldwide.
